Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$95.54 USD
+1.93 (2.06%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $95.47 -0.07 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 711 | 945 | 477 | 872 | 484 |
Receivables | 43 | 37 | 37 | 25 | 23 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 21 | 30 | 22 | 9 | 0 |
Other Current Assets | 33 | 35 | 18 | 22 | 10 |
Total Current Assets | 808 | 1,047 | 554 | 928 | 517 |
Net Property & Equipment | 42 | 33 | 31 | 34 | 38 |
Investments & Advances | 84 | 161 | 558 | 678 | 64 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 41 | 27 | 20 | 11 | 15 |
Total Assets | 1,049 | 1,350 | 1,252 | 1,718 | 708 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 3 | 8 | 4 | 5 |
Current Portion Long-Term Debt | 30 | 17 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 7 |
Accrued Expenses | 128 | 131 | 122 | 106 | 89 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 40 | 22 | 12 | 13 | 6 |
Total Current Liabilities | 215 | 183 | 150 | 131 | 106 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 14 | 25 | 29 | 40 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 209 | 122 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 409 | 423 | 3 | 7 | 8 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 919 | 835 | 281 | 248 | 243 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,474 | 2,358 | 2,250 | 2,107 | 1,412 |
Retained Earnings | -2,340 | -1,833 | -1,275 | -631 | -945 |
Other Equity | -4 | -10 | -4 | -5 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 131 | 515 | 971 | 1,470 | 464 |
Total Liabilities & Shareholder's Equity | 1,049 | 1,350 | 1,252 | 1,718 | 708 |
Total Common Equity | 131 | 515 | 971 | 1,470 | 464 |
Shares Outstanding | 60.70 | 59.80 | 58.80 | 55.70 | 49.20 |
Book Value Per Share | 2.15 | 8.61 | 16.51 | 26.39 | 9.44 |
Fiscal Year End for Blueprint Medicines Corporation falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 764 | 648 | 711 | 713 | 723 |
Receivables | 85 | 60 | 43 | 41 | 38 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 15 | 31 | 21 | 16 | 17 |
Other Current Assets | 40 | 38 | 33 | 37 | 33 |
Total Current Assets | 904 | 777 | 808 | 808 | 811 |
Net Property & Equipment | 40 | 42 | 42 | 41 | 37 |
Investments & Advances | 133 | 115 | 84 | 142 | 142 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 58 | 33 | 41 | 39 | 39 |
Total Assets | 1,204 | 1,038 | 1,049 | 1,105 | 1,106 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 5 | 7 | 7 |
Current Portion Long-Term Debt | 48 | 30 | 30 | 30 | 18 |
Current Portion Capital Leases | 13 | 0 | 0 | 0 | 0 |
Accrued Expenses | 121 | 107 | 128 | 110 | 101 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 57 | 52 | 40 | 38 | 32 |
Total Current Liabilities | 244 | 207 | 215 | 197 | 169 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 8 | 5 | 5 | 5 | 5 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 339 | 209 | 209 | 208 | 122 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 218 | 409 | 408 | 412 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 883 | 728 | 919 | 903 | 795 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,625 | 2,565 | 2,474 | 2,434 | 2,411 |
Retained Earnings | -2,301 | -2,251 | -2,340 | -2,229 | -2,095 |
Other Equity | -4 | -4 | -4 | -3 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 320 | 311 | 131 | 203 | 311 |
Total Liabilities & Shareholder's Equity | 1,204 | 1,038 | 1,049 | 1,105 | 1,106 |
Total Common Equity | 320 | 311 | 131 | 203 | 311 |
Shares Outstanding | 63.30 | 61.20 | 60.70 | 60.70 | 60.60 |
Book Value Per Share | 5.06 | 5.08 | 2.15 | 3.34 | 5.13 |